These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 14963350)

  • 81. Karyometry detects subvisual differences in chromatin organisation state between non-recurrent and recurrent papillary urothelial neoplasms of low malignant potential.
    Scarpelli M; Montironi R; Tarquini LM; Hamilton PW; López Beltran A; Ranger-Moore J; Bartels PH
    J Clin Pathol; 2004 Nov; 57(11):1201-7. PubMed ID: 15509685
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Clinical observations of plasma fibronectin in patients with urological malignant disease].
    Fujimoto N; Ozu K; Inatomi H; Okamura T; Sugita A
    Nihon Hinyokika Gakkai Zasshi; 1991 Jun; 82(6):984-9. PubMed ID: 1881018
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Elevation of serum CA19-9 levels in benign diseases.
    Ito S; Gejyo F
    Intern Med; 1999 Nov; 38(11):840-1. PubMed ID: 10563741
    [No Abstract]   [Full Text] [Related]  

  • 84. The lymphocyte-monocyte ratio in clinical practice.
    Balta S; Demırer Z; Aparci M; Yildirim AO; Ozturk C
    J Clin Pathol; 2016 Jan; 69(1):88-9. PubMed ID: 26307075
    [No Abstract]   [Full Text] [Related]  

  • 85. The modified Makari skin test in urology--is it significant?
    Munson KW; Tee DE
    Br J Urol; 1977; 49(7):569-73. PubMed ID: 339985
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Response to Pyrotinib in a Patient with Metastatic Bladder Urothelial Carcinoma Harboring HER2 V842I Mutation: A Case Report.
    Li S; Liu Q; Liu M; Liu T
    Cancer Manag Res; 2022; 14():2927-2932. PubMed ID: 36200096
    [TBL] [Abstract][Full Text] [Related]  

  • 87. High Carbohydrate Antigen 19-9 Levels Indicate Poor Prognosis of Upper Tract Urothelial Carcinoma.
    Jeong SH; Han JH; Jeong CW; Kim HH; Kwak C; Yuk HD; Ku JH
    Front Oncol; 2022; 12():858813. PubMed ID: 35912192
    [TBL] [Abstract][Full Text] [Related]  

  • 88. CA 19-9 as a serum marker in urothelial carcinoma.
    Pall M; Iqbal J; Singh SK; Rana SV
    Urol Ann; 2012 May; 4(2):98-101. PubMed ID: 22629005
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Significance of serum concentrations of E-selectin and CA19-9 in the prognosis of colorectal cancer.
    Sato H; Usuda N; Kuroda M; Hashimoto S; Maruta M; Maeda K
    Jpn J Clin Oncol; 2010 Nov; 40(11):1073-80. PubMed ID: 20576794
    [TBL] [Abstract][Full Text] [Related]  

  • 90. CA19-9 as a serum marker for poor prognosis in urothelial carcinoma.
    Sashide K; Isobe H; Wakumoto Y; Hanazawa K; Fujita K; Fujime M
    Urol Int; 2004; 72(2):112-7. PubMed ID: 14963350
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Clinical usefulness of CEA, CA19-9, and CYFRA 21-1 as tumor markers for urothelial bladder carcinoma.
    Washino S; Hirai M; Matsuzaki A; Kobayashi Y
    Urol Int; 2011; 87(4):420-8. PubMed ID: 22041857
    [TBL] [Abstract][Full Text] [Related]  

  • 92. CA19-9 as a serum marker for poor prognosis in urothelial carcinoma.
    Suzuki K
    Urol Int; 2004; 73(4):357. PubMed ID: 15604583
    [No Abstract]   [Full Text] [Related]  

  • 93. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer.
    Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Wang HS; Chen PM
    Hepatogastroenterology; 2002; 49(43):160-4. PubMed ID: 11941943
    [TBL] [Abstract][Full Text] [Related]  

  • 94. High Serum CA19-9 Concentration Indicates High Chemosensitivity and Better Survival in Advanced Urothelial Carcinoma.
    Yaegashi H; Izumi K; Kadomoto S; Naito R; Makino T; Iwamoto H; Nohara T; Shigehara K; Kadono Y; Mizokami A
    Anticancer Res; 2019 Jan; 39(1):375-380. PubMed ID: 30591483
    [TBL] [Abstract][Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.